TK1在乳腺导管癌中的表达及其临床病理学意义分析

目的检测胸苷激酶-1(Thymidine Kinase-1,TK1)在乳腺导管癌的表达情况,并分析与Ki67、ER、PR、C-erbB-2等临床病理学指标的关系,以及其与患者预后的关系。方法收集40例乳腺浸润性导管癌(invasive ductal carci-noma,IDC)组织,其中31例含有导管原位癌(ductal carcinoma in situ,DCIS)的成分,37例癌旁可见正常的乳腺组织(normal breast tissues,NBT)。采用免疫组织化学的方法检测40例乳腺癌组织中TK1、Ki67、ER、PR、C-erbB-2。结果 TK1在乳腺癌组织中浸润性导管癌的表达率为57.5%(23/40),导管原位癌为51.6%(16/31),癌旁正常的乳腺组织为0%(0/37),三者之间的表达率差异有统计学意义(P<0.001)。TK1表达与年龄、月经、肿瘤大小、淋巴结转移与否、TNM分期、ER、PR、C-erbB-2无关(P>0.05),与组织学分级有关(P<0.05)。TK1在浸润性导管癌Ⅰ级的表达率为20%(2/10),Ⅱ级为76%(19/25),Ⅲ级为40%(2/5),以组织学Ⅱ级为最高。TK1的表达与Ki67相关(r=0.738,P<0.001)。TK1阳性组的累积生存率低于TK1阴性组,并且TK1和Ki67均阳性的为最低。结论 TK1在乳腺癌组织中高表达,对于导管原位癌的诊断具有辅助价值。TK1是患者预后不良的一项指标。

Study on TK1 expression in breast ductal carcinoma and its clinicalpathological significance

Objective To study the expression of TK1 in breast ductal carcinoma. To investigate the correlation of TK1 with Ki67, ER, PR, C erB-2, the clinical factors and pathological factors in breast cancer. To analyze the effect of TK1 and Ki67 on survival rate of breast carcinoma. Methods TK1, Ki67, ER, PR, and C erbB-2 were detected in 40 cases of breast carcinoma with immunohistoehemical staining. Results The expression rate of TK1 was 57.5% （23/40） in invasive duetal car cinoma （IDC）, 51.6% （16/31） in ductal carcinoma in situ （DCIS）, 0% （0/37） in normal breast tissues （NBT）. There was significant difference between IDC, DCIS, and NBT （P〈0. 001）. TK1 showed a correlation with tumor grade （P〈0.05）, not with age, tumor size, lymph node metastasis, TNM stage, ER and PR, and C erbB-2. The expression rate of TK1 was highest in IDC grade Ⅱ （76%, 19/25）, while the rate was 20% （2/10） in IDC grade I , and 40% （2/5） in IDC grade Ⅲ. The expression of TK1 correlated with Ki67 （r=0. 738, P〈0. 001）. The cumulative survival rate of TK1 positive cases was lower than that of TK1 negtive cases and the rate of TK1＆Ki67 positive cases was lowest. Conclusion TK1 expresses high in breast cancer, and it assists in the diagnosis of DCIS. TK1 is a mark of poor prognosis.